Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects
Phase 1
Completed
- Conditions
- Obesity
- Registration Number
- NCT00148382
- Lead Sponsor
- Alizyme
- Brief Summary
The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese
- Detailed Description
Obesity is a significant and increasing clinical problem. There is a need for effective therapeutic agents to help people reduce weight. ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a person's diet, leading to weight reduction.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- Obese, otherwise-healthy subjects
- Body mass index 30-45kg/m2
Exclusion Criteria
- Women who are pregnant or breast feeding
- Any drug treatment within 2 weeks of commencement of dosing in this study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Pharmacokinetics of metabolites of ATL-962
- Secondary Outcome Measures
Name Time Method Effect of ATL-962 on faecal fat excretion Safety and tolerability of ATL-962
Trial Locations
- Locations (1)
SFBCI
🇺🇸Miami, Florida, United States